\n

Presentation

\nSiesta: Each tablet contains Bromazepam USP 3 mg. \n \n

\n

Description

\nSiesta is a pyridylbenzodiazepine compound with anxiolytic properties. In low dosage, it diminishes anxiety, tension and nervousness. In high dosage, the sedative and muscle-relaxant properties appear. \n \n

\n

Indications

\nSiesta is indicated in the following diseases: \n \n* Emotional disturbances: Anxiety and tension states, as adjuvant therapy for anxiety in depressed patients, nervous tension, restlessness, and anxiety- and tension- related insomnia. As an adjuvant to treatment of underlying disease responsible for functional or psychosomatic impairments of various organs caused by anxiety and tension. \n \n* Cardiovascular and respiratory systems: Pseudoangina pectoris, precordial anxiety, tachycardia, emotiogenic hypertension, dyspnea, and hyperventilation. \n \n* Gastrointestinal tract: Irritable bowel syndrome, ulcerative colitis, epigastric pain, spasm, meteorism, and diarrhoea. \n \n* Urogenital tract: Irritable bladder, urinary frequency and dysmenorrhea. \n \n* Other psychosomatic disturbances: Psychogenic headache, psychogenic dermatoses. \n \nSiesta is suitable for treatment of anxiety and tension states due to chronic organic disease and as an adjuvant to psychotherapy in psychoneurosis. \n \n

\n

Dosage & Administration

\nAdults: The optimum dosage and frequency of administration of Bromazepam is based on the individual patient, the severity of symptoms and previous psychotropic drug history. \nAverage dose for outpatient therapy: 1.5 - 3 mg 3 times daily. \nSevere cases, especially in hospitals: 6 - 12 mg 2 - 3 times daily. \nTreatment of outpatients should begin with low doses, gradually increasing to the optimum level. In general, the total duration of treatment should not exceed 8-12 weeks including a tapering-off period. In certain cases, treatment may need to be continued beyond the maximum recommended duration but only after a careful reassessment of the patient's condition and indications. \nElderly patients: Doses should not exceed half those normally recommended. \nChildren: Bromazepam is not for paediatric use. \n \n

\n

Side Effects

\nCommon side effects include drowsiness, sedation, unsteadiness and ataxia. These are dose-related and may persist into the following day, even after a single dose. Other side effects are rare and include headache, vertigo, hypotension, gastrointestinal upsets, skin rashes, visual disturbances and urinary retention. \n \n

\n

Precautions

\nIn patients with chronic pulmonary insufficiency, and in patients with chronic renal or hepatic disease, dosage may need to be reduced. \nBromazepam should not be used alone to treat depression or anxiety associated with depression. \nBromazepam should be used with extreme caution in patients with a history of alcohol or drug abuse. \n \n

\n

Use in Pregnancy & Lactation

\nPregnancy: The safety of Bromazepam in pregnant women has not been established. Bromazepam should not be used during pregnancy, especially during the first and last trimesters, unless there are compelling reasons. \nLactation: Benzodiazepines have been detected in breast milk. If possible, the use of Bromazepam should be avoided during lactation. \n \n

\n

Drug Interaction

\nIf Bromazepam is combined with other centrally acting drugs, such as neuroleptics, tranquilizers, antidepressants, hypnotics, narcotic analgesics and anaesthetics, its CNS sedation effect may be increased. \n \n

\n

Over Dose

\nManifestations of overdosage include somnolence, confusion, and respiratory and cardiovascular depression with coma in severe cases. \n \n

\n

Commercial Pack

\nSiesta: Each box contains 3 blister strips of 10 tablets. \n \n